28 results on '"Reindl, Markus"'
Search Results
2. Age-dependent favorable visual recovery despite significant retinal atrophy in pediatric MOGAD: how much retina do you really need to see well?
- Author
-
Havla, Joachim, Pakeerathan, Thivya, Schwake, Carolin, Bennett, Jeffrey L., Kleiter, Ingo, Felipe-Rucián, Ana, Joachim, Stephanie C., Lotz-Havla, Amelie S., Kümpfel, Tania, Krumbholz, Markus, Wendel, Eva M., Reindl, Markus, Thiels, Charlotte, Lücke, Thomas, Hellwig, Kerstin, Gold, Ralf, Rostasy, Kevin, and Ayzenberg, Ilya
- Published
- 2021
- Full Text
- View/download PDF
3. German translation, cultural adaptation and validation of the unidimensional self-efficacy scale for multiple sclerosis
- Author
-
Seebacher, Barbara, Mills, Roger J., Reindl, Markus, Zamarian, Laura, Kircher, Simone, Brenneis, Christian, Ehling, Rainer, and Deisenhammer, Florian
- Published
- 2021
- Full Text
- View/download PDF
4. Serum GFAP and NfL as disease severity and prognostic biomarkers in patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder
- Author
-
Schindler, Patrick, Grittner, Ulrike, Oechtering, Johanna, Leppert, David, Siebert, Nadja, Duchow, Ankelien S., Oertel, Frederike C., Asseyer, Susanna, Kuchling, Joseph, Zimmermann, Hanna G., Brandt, Alexander U., Benkert, Pascal, Reindl, Markus, Jarius, Sven, Paul, Friedemann, Bellmann-Strobl, Judith, Kuhle, Jens, and Ruprecht, Klemens
- Published
- 2021
- Full Text
- View/download PDF
5. Cerebrospinal fluid findings in patients with myelin oligodendrocyte glycoprotein (MOG) antibodies. Part 1: Results from 163 lumbar punctures in 100 adult patients
- Author
-
Jarius, Sven, Pellkofer, Hannah, Siebert, Nadja, Korporal-Kuhnke, Mirjam, Hümmert, Martin W., Ringelstein, Marius, Rommer, Paulus S., Ayzenberg, Ilya, Ruprecht, Klemens, Klotz, Luisa, Asgari, Nasrin, Zrzavy, Tobias, Höftberger, Romana, Tobia, Rafik, Buttmann, Mathias, Fechner, Kai, Schanda, Kathrin, Weber, Martin, Asseyer, Susanna, Haas, Jürgen, Lechner, Christian, Kleiter, Ingo, Aktas, Orhan, Trebst, Corinna, Rostasy, Kevin, Reindl, Markus, Kümpfel, Tania, Paul, Friedemann, and Wildemann, Brigitte
- Published
- 2020
- Full Text
- View/download PDF
6. Induction of aquaporin 4-reactive antibodies in Lewis rats immunized with aquaporin 4 mimotopes
- Author
-
Tsymala, Irina, Nigritinou, Magdalini, Zeka, Bleranda, Schulz, Rouven, Niederschick, Felix, Matković, Mia, Bauer, Isabel J., Szalay, Michael, Schanda, Kathrin, Lerch, Magdalena, Misu, Tatsuro, Fujihara, Kazuo, Bennett, Jeffrey L., Dahle, Charlotte, Pache, Florence, Rommer, Paulus, Leutmezer, Fritz, Illes, Zsolt, Leite, Maria Isabel, Palace, Jacqueline, Scholze, Petra, Reindl, Markus, Lassmann, Hans, and Bradl, Monika
- Published
- 2020
- Full Text
- View/download PDF
7. High-salt diet does not boost neuroinflammation and neurodegeneration in a model of α-synucleinopathy
- Author
-
Heras-Garvin, Antonio, Refolo, Violetta, Reindl, Markus, Wenning, Gregor K., and Stefanova, Nadia
- Published
- 2020
- Full Text
- View/download PDF
8. Optical coherence tomography in myelin-oligodendrocyte-glycoprotein antibody-seropositive patients: a longitudinal study
- Author
-
Oertel, Frederike C., Outteryck, Olivier, Knier, Benjamin, Zimmermann, Hanna, Borisow, Nadja, Bellmann-Strobl, Judith, Blaschek, Astrid, Jarius, Sven, Reindl, Markus, Ruprecht, Klemens, Meinl, Edgar, Hohlfeld, Reinhard, Paul, Friedemann, Brandt, Alexander U., Kümpfel, Tania, and Havla, Joachim
- Published
- 2019
- Full Text
- View/download PDF
9. Aquaporin 4-specific T cells and NMO-IgG cause primary retinal damage in experimental NMO/SD
- Author
-
Zeka, Bleranda, Hastermann, Maria, Kaufmann, Nathalie, Schanda, Kathrin, Pende, Marko, Misu, Tatsuro, Rommer, Paulus, Fujihara, Kazuo, Nakashima, Ichiro, Dahle, Charlotte, Leutmezer, Fritz, Reindl, Markus, Lassmann, Hans, and Bradl, Monika
- Subjects
Aquaporin 4 ,Medicin och hälsovetenskap ,genetic structures ,Research ,T-Lymphocytes ,Neuromyelitis Optica ,Klinisk medicin ,Retinitis ,Medical and Health Sciences ,eye diseases ,Axons ,Retina ,Disease Models, Animal ,Rats, Inbred Lew ,Astrocytes ,Immunoglobulin G ,Animals ,sense organs ,Clinical Medicine - Abstract
Neuromyelitis optica/spectrum disorder (NMO/SD) is a severe, inflammatory disease of the central nervous system (CNS). In the majority of patients, it is associated with the presence of pathogenic serum autoantibodies (the so-called NMO-IgGs) directed against the water channel aquaporin 4 (AQP4), and with the formation of large, astrocyte-destructive lesions in spinal cord and optic nerves. A large number of recent studies using optical coherence tomography (OCT) demonstrated that damage to optic nerves in NMO/SD is also associated with retinal injury, as evidenced by retinal nerve fiber layer (RNFL) thinning and microcystic inner nuclear layer abnormalities. These studies concluded that retinal injury in NMO/SD patients results from secondary neurodegeneration triggered by optic neuritis. However, the eye also contains cells expressing AQP4, i.e., Müller cells and astrocytes in the retina, epithelial cells of the ciliary body, and epithelial cells of the iris, which raised the question whether the eye can also be a primary target in NMO/SD. Here, we addressed this point in experimental NMO/SD (ENMO) induced in Lewis rat by transfer of AQP4268–285-specific T cells and NMO-IgG. We show that these animals show retinitis and subsequent dysfunction/damage of retinal axons and neurons, and that this pathology occurs independently of the action of NMO-IgG. We further show that in the retinae of ENMO animals Müller cell side branches lose AQP4 reactivity, while retinal astrocytes and Müller cell processes in the RNFL/ganglionic cell layers are spared. These changes only occur in the presence of both AQP4268–285-specific T cells and NMO-IgG. Cumulatively, our data show that damage to retinal cells can be a primary event in NMO/SD.
- Published
- 2016
10. Human antibodies against the myelin oligodendrocyte glycoprotein can cause complement-dependent demyelination.
- Author
-
Peschl, Patrick, Schanda, Kathrin, Zeka, Bleranda, Given, Katherine, Böhm, Denise, Ruprecht, Klemens, Saiz, Albert, Lutterotti, Andreas, Rostásy, Kevin, Höftberger, Romana, Berger, Thomas, Macklin, Wendy, Lassmann, Hans, Bradl, Monika, Bennett, Jeffrey L., and Reindl, Markus
- Subjects
DEMYELINATION ,IMMUNOGLOBULINS ,MYELIN ,GLYCOPROTEINS ,CENTRAL nervous system diseases ,ANIMAL experimentation ,CEREBELLUM ,COMPLEMENT (Immunology) ,EPITHELIAL cells ,RESEARCH methodology ,MICE ,RATS ,RESEARCH funding ,TISSUE culture ,MEMBRANE glycoproteins ,NEUROMYELITIS optica - Abstract
Background: Antibodies to the myelin oligodendrocyte glycoprotein (MOG) are associated with a subset of inflammatory demyelinating diseases of the central nervous system such as acute disseminated encephalomyelitis and neuromyelitis optica spectrum disorders. However, whether human MOG antibodies are pathogenic or an epiphenomenon is still not completely clear. Although MOG is highly conserved within mammals, previous findings showed that not all human MOG antibodies bind to rodent MOG. We therefore hypothesized that human MOG antibody-mediated pathology in animal models may only be evident using species-specific MOG antibodies.Methods: We screened 80 human MOG antibody-positive samples for their reactivity to mouse and rat MOG using either a live cell-based assay or immunohistochemistry on murine, rat, and human brain tissue. Selected samples reactive to either human MOG or rodent MOG were subsequently tested for their ability to induce complement-mediated damage in murine organotypic brain slices or enhance demyelination in an experimental autoimmune encephalitis (EAE) model in Lewis rats. The MOG monoclonal antibody 8-18-C5 was used as a positive control.Results: Overall, we found that only a subset of human MOG antibodies are reactive to mouse (48/80, 60%) or rat (14/80, 18%) MOG. Purified serum antibodies from 10 human MOG antibody-positive patients (8/10 reactive to mouse MOG, 6/10 reactive to rat MOG), 3 human MOG-negative patients, and 3 healthy controls were tested on murine organotypic brain slices. Purified IgG from one patient with high titers of anti-human, mouse, and rat MOG antibodies and robust binding to myelin tissue produced significant, complement-mediated myelin loss in organotypic brain slices, but not in the EAE model. Monoclonal 8-18-C5 MOG antibody caused complement-mediated demyelination in both the organotypic brain slice model and in EAE.Conclusion: This study shows that a subset of human MOG antibodies can induce complement-dependent pathogenic effects in a murine ex vivo animal model. Moreover, a high titer of species-specific MOG antibodies may be critical for demyelinating effects in mouse and rat animal models. Therefore, both the reactivity and titer of human MOG antibodies must be considered for future pathogenicity studies. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
11. MOG antibody seropositivity in a patient with encephalitis: beyond the classical syndrome.
- Author
-
Mariotto, Sara, Monaco, Salvatore, Peschl, Patrick, Coledan, Ilaria, Mazzi, Romualdo, Höftberger, Romana, Reindl, Markus, and Ferrari, Sergio
- Subjects
MYELIN oligodendrocyte glycoprotein ,CENTRAL nervous system viral diseases ,ENCEPHALITIS ,MYELITIS ,NEURITIS - Abstract
Background: The presence of circulating anti-myelin oligodendrocyte glycoprotein antibodies (MOG-Abs) has been described in sera of patients with different inflammatory conditions of the central nervous system. In adults the core clinical feature is usually characterised by acute myelitis and/or optic neuritis. We here report an atypical case with serum and cerebrospinal fluid MOG-Abs and a clinical picture suggestive for acute encephalitis.Case Presentation: A 31-year-old Indian man presented with altered mental status, slight fever, and ataxia. Brain magnetic resonance imaging noted a widespread involvement of the white matter associated with slight cortical and subcortical damage in absence of contrast enhancement. An extensive infectious screening resulted negative while autoimmune analysis revealed the presence of MOG-Abs, detected with live cell-based assay. After treatment with intravenous immunoglobulins a marked and prompt clinical and radiological improvement was observed.Conclusions: To date, several areas of uncertainty still remain regarding clinical features and prognosis of subjects with MOG-Abs. The description of atypical cases is crucial, since recognition of this condition leads to prompt treatment and better prognosis, as in the case here reported. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
12. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 4: Afferent visual system damage after optic neuritis in MOG-IgG-seropositive versus AQP4-IgG-seropositive patients.
- Author
-
Pache, Florence, Zimmermann, Hanna, Mikolajczak, Janine, Schumacher, Sophie, Lacheta, Anna, Oertel, Frederike C., Bellmann-Strobl, Judith, Jarius, Sven, Wildemann, Brigitte, Reindl, Markus, Waldman, Amy, Soelberg, Kerstin, Asgari, Nasrin, Ringelstein, Marius, Aktas, Orhan, Gross, Nikolai, Buttmann, Mathias, Ach, Thomas, Ruprecht, Klemens, and Paul, Friedemann
- Subjects
MYELIN oligodendrocyte glycoprotein ,OPTIC neuritis ,VISION disorders ,OPTICAL coherence tomography ,HEALTH outcome assessment ,VISUAL evoked potentials ,VISUAL acuity ,PATIENTS ,DIAGNOSIS - Abstract
Background: Antibodies against myelin oligodendrocyte glycoprotein (MOG-IgG) have been reported in patients with aquaporin-4 antibody (AQP4-IgG)-negative neuromyelitis optica spectrum disorders (NMOSD). The objective of this study was to describe optic neuritis (ON)-induced neuro-axonal damage in the retina of MOG-IgG-positive patients in comparison with AQP4-IgG-positive NMOSD patients. Methods: Afferent visual system damage following ON was bilaterally assessed in 16 MOG-IgG-positive patients with a history of ON and compared with that in 16 AQP4-IgG-positive NMOSD patients. In addition, 16 healthy controls matched for age, sex, and disease duration were analyzed. Study data included ON history, retinal optical coherence tomography, visual acuity, and visual evoked potentials. Results: Eight MOG-IgG-positive patients had a previous diagnosis of AQP4-IgG-negative NMOSD with ON and myelitis, and eight of (mainly recurrent) ON. Twenty-nine of the 32 eyes of the MOG-IgG-positive patients had been affected by at least one episode of ON. Peripapillary retinal nerve fiber layer thickness (pRNFL) and ganglion cell and inner plexiform layer volume (GCIP) were significantly reduced in ON eyes of MOG-IgG-positive patients (pRNFL = 59 ± 23 μm; GCIP = 1.50 ± 0.34 mm3) compared with healthy controls (pRNFL = 99 ± 6 μm, p < 0.001; GCIP =1.97 ± 0.11 mm3, p < 0.001). Visual acuity was impaired in eyes after ON in MOG-IgG-positive patients (0.35 ± 0.88 logMAR). There were no significant differences in any structural or functional visual parameters between MOG-IgGpositive and AQP4-IgG-positive patients (pRNFL: 59 ± 21 μm; GCIP: 1.41 ± 0.27 mm3; Visual acuity = 0.72 ± 1.09 logMAR). Importantly, MOG-IgG-positive patients had a significantly higher annual ON relapse rate than AQP4-IgGpositive patients (median 0.69 vs. 0.29 attacks/year, p = 0.004), meaning that on average a single ON episode caused less damage in MOG-IgG-positive than in AQP4-IgG-positive patients. pRNFL and GCIP loss correlated with the number of ON episodes in MOG-IgG-positive patients (p < 0.001), but not in AQP4-IgG-positive patients. Conclusions: Retinal neuro-axonal damage and visual impairment after ON in MOG-IgG-positive patients are as severe as in AQP4-IgG-positive NMOSD patients. In MOG-IgG-positive patients, damage accrual may be driven by higher relapse rates, whereas AQP4-IgG-positive patients showed fewer but more severe episodes of ON. Given the marked damage in some of our MOG-IgG-positive patients, early diagnosis and timely initiation and close monitoring of immunosuppressive therapy are important. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
13. Characterization of the binding pattern of human aquaporin-4 autoantibodies in patients with neuromyelitis optica spectrum disorders.
- Author
-
Tuller, Friederike, Holzer, Hannah, Schanda, Kathrin, Aboulenein-Djamshidian, Fahmy, Höftberger, Romana, Khalil, Michael, Seifert-Held, Thomas, Leutmezer, Fritz, Berger, Thomas, and Reindl, Markus
- Subjects
AQUAPORINS ,AUTOANTIBODIES ,NEUROMYELITIS optica ,AUTOIMMUNE diseases ,AMINO acids ,CARRIER proteins ,ANTIGENS ,EPITHELIAL cells ,FLOW cytometry ,GENETIC techniques ,IMMUNOLOGY technique ,MATHEMATICAL models ,MEMBRANE proteins ,GENETIC mutation ,PROTEINS ,THEORY - Abstract
Background: The discovery of a highly specific antibody against the aquaporin-4 (AQP4) water channel (AQP4-IgG) unified the spectrum of neuromyelitis optica spectrum disorders (NMOSD), which are considered to be antibody-mediated autoimmune diseases. The AQP4 water channel is located on astrocytic end-feet processes and consists of six transmembrane helical domains forming three extracellular loops A, C, and E in which defined amino acids were already proven to be critical for AQP4-IgG binding. However, the clinical relevance of these findings is unclear. Therefore, we have characterized the epitope specificity of AQP4-IgG-positive NMOSD patients.Methods: We established a cell-based flow cytometry assay for the quantitative detection of AQP4-IgG-positive serum samples. Human embryonic kidney (HEK) cells were transiently transfected with an EmGFP-tagged AQP4-M23, AQP4-M1, or six AQP4-M23 extracellular loop mutants including two mutations in loop A (serial AA substitution, insertion of a myc-tag), two in loop C (N153Q, insertion of a myc-tag), and two in loop E (H230G, insertion of a myc-tag). Fourty-seven baseline and 49 follow-up serum samples and six paired cerebrospinal fluid (CSF) baseline samples of 47 AQP4-IgG-positive Austrian NMOSD patients were then tested for their binding capability to AQP4-M1 and AQP4-M23 isoforms and these six extracellular loop mutants.Results: Overall, we could identify two broad patterns of antibody recognition based on differential sensitivity to mutations in extracellular loop A. Pattern A was characterized by reduced binding to the two mutations in loop A, whereas pattern B had only partial or no reduced binding to these mutations. These two patterns were not associated with significant differences in demographic and clinical parameters or serum titers in this retrospective study. Interestingly, we found a change of AQP4-IgG epitope recognition pattern in seven of 20 NMOSD patients with available follow-up samples. Moreover, we found different binding patterns in five of six paired CSF versus serum samples, with a predominance of pattern A in CSF.Conclusions: Our study demonstrates that AQP4-IgG in sera of NMOSD patients show distinct patterns of antibody recognition. The clinical and diagnostic relevance of these findings have to be addressed in prospective studies. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
14. An antibody microarray analysis of serum cytokines in neurodegenerative Parkinsonian syndromes.
- Author
-
Mahlknecht, Philipp, Stemberger, Sylvia, Sprenger, Fabienne, Rainer, Johannes, Hametner, Eva, Kirchmair, Rudolf, Grabmer, Christoph, Scherfler, Christoph, Wenning, Gregor K., Seppi, Klaus, Poewe, Werner, and Reindl, Markus
- Subjects
MICROARRAY technology ,CYTOKINES ,PARKINSONIAN disorders ,NEURODEGENERATION ,ATROPHY - Abstract
Background: Microarray technology may offer a new opportunity to gain insight into disease-specific global protein expression profiles. The present study was performed to apply a serum antibody microarray to screen for differentially regulated cytokines in Parkinson's disease (PD), multiple system atrophy (MSA), progressive supranuclear palsy (PSP) and corticobasal syndrome (CBS). Results: Serum samples were obtained from patients with clinical diagnoses of PD (n = 117), MSA (n = 31) and PSP/CBS (n = 38) and 99 controls. Cytokine profiles of sera from patients and controls were analyzed with a semiquantitative human antibody array for 174 cytokines and the expression of 12 cytokines was found to be significantly altered. In a next step, results from the microarray experiment were individually validated by different immunoassays. Immunoassay validation confirmed a significant increase of median PDGF-BB levels in patients with PSP/CBS, MSA and PD and a decrease of median prolactin levels in PD. However, neither PDGF-BB nor prolactin were specific biomarkers to discriminate PSP/CBS, MSA, PD and controls. Conclusions: In our unbiased cytokine array based screening approach and validation by a different immunoassay only two of 174 cytokines were significantly altered between patients and controls. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
15. Nogo receptor is involved in the adhesion of dendritic cells to myelin.
- Author
-
McDonald, Claire L, Steinbach, Karin, Kern, Florian, Schweigreiter, Rüdiger, Martin, Roland, Bandtlow, Christine E, and Reindl, Markus
- Subjects
NEUROLOGICAL research ,DENDRITIC cells ,ANTIGEN presenting cells ,MYELOID leukemia ,BONE marrow diseases ,PROTEIN metabolism ,ANIMALS ,CELL differentiation ,CELL physiology ,CELL receptors ,CYTOKINES ,GLYCOPROTEINS ,MICE ,MONOCYTES ,NERVE tissue ,NERVE tissue proteins ,PROTEINS ,RESEARCH funding ,LYMPHOCYTE subsets ,PHYSIOLOGY - Abstract
Background: Nogo-66 receptor NgR1 and its structural homologue NgR2 are binding proteins for a number of myelin-associated inhibitory factors. After neuronal injury, these inhibitory factors are responsible for preventing axonal outgrowth via their interactions with NgR1 and NgR2 expressed on neurons. In vitro, cells expressing NgR1/2 are inhibited from adhering to and spreading on a myelin substrate. Neuronal injury also results in the presence of dendritic cells (DCs) in the central nervous system, where they can come into contact with myelin debris. The exact mechanisms of interaction of immune cells with CNS myelin are, however, poorly understood.Methods: Human DCs were differentiated from peripheral blood monocytes and mouse DCs were differentiated from wild type and NgR1/NgR2 double knockout bone marrow precursors. NgR1 and NgR2 expression were determined with quantitative real time PCR and immunoblot, and adhesion of cells to myelin was quantified.Results: We demonstrate that human immature myeloid DCs express NgR1 and NgR2, which are then down-regulated upon maturation. Human mature DCs also adhere to a much higher extent to a myelin substrate than immature DCs. We observe the same effect when the cells are plated on Nogo-66-His (binding peptide for NgR1), but not on control proteins. Mature DCs taken from Ngr1/2 knockout mice adhere to a much higher extent to myelin compared to wild type mouse DCs. In addition, Ngr1/2 knockout had no effect on in vitro DC differentiation or phenotype.Conclusions: These results indicate that a lack of NgR1/2 expression promotes the adhesion of DCs to myelin. This interaction could be important in neuroinflammatory disorders such as multiple sclerosis in which peripheral immune cells come into contact with myelin debris. [ABSTRACT FROM AUTHOR]- Published
- 2011
- Full Text
- View/download PDF
16. Nogo-B is associated with cytoskeletal structures in human monocyte-derived macrophages.
- Author
-
Schanda, Kathrin, Hermann, Martin, Stefanova, Nadia, Gredler, Viktoria, Bandtlow, Christine, and Reindl, Markus
- Abstract
Background: The reticulon Nogo-B participates in cellular and immunological processes in murine macrophages. Since leukocytes are an essential part of the immune system in health and disease, we decided to investigate the expression of Nogo-A, Nogo-B and Nogo-C in different human immune cell subpopulations. Furthermore, we analyzed the localization of Nogo-B in human monocyte-derived macrophages by indirect immunofluorescence stainings to gain further insight into its possible function. Findings: We describe an association of Nogo-B with cytoskeletal structures and the base of filopodia, but not with focal or podosomal adhesion sites of monocyte-derived macrophages. Nogo-B positive structures are partially co-localized with RhoA staining and Rac1 positive membrane ruffles. Furthermore, Nogo-B is associated with the tubulin network, but not accumulated in the Golgi region. Although Nogo-B is present in the endoplasmic reticulum, it can also be translocated to large cell protrusions or the trailing end of migratory cells, where it is homogenously distributed. Conclusions: Two different Nogo-B staining patterns can be distinguished in macrophages: firstly we observed ER-independent Nogo-B localization in cell protrusions and at the trailing end of migrating cells. Secondly, the localization of Nogo-B in actin/RhoA/Rac1 positive regions supports an influence on cytoskeletal organization. To our knowledge this is the first report on Nogo-B expression at the base of filopodia, thus providing further insight into the distribution of this protein. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
17. Murine malaria is associated with significant hearing impairment.
- Author
-
Schmutzhard, Joachim, Kositz, Christian H., Lackner, Peter, Dietmann, Anelia, Fischer, Marlene, Glueckert, Rudolf, Reindl, Markus, Stephan, Kurt, Riechelmann, Herbert, Schrott-Fischer, Annelies, and Schmutzhard, Erich
- Subjects
MALARIA treatment ,HEARING disorders ,COGNITION disorders ,THERAPEUTICS ,MEDICAL research - Abstract
Background: Plasmodium falciparum malaria has been suspected to cause hearing loss. Developmental, cognitive and language disorders have been observed in children, surviving cerebral malaria. This prospective study aims to evaluate whether malaria influences hearing in mice. Methods: Twenty mice were included in a standardized murine cerebral malaria model. Auditory evoked brainstem responses were assessed before infection and at the peak of the illness. Results: A significant hearing impairment could be demonstrated in mice with malaria, especially the cerebral form. The control group did not show any alterations. No therapy was used. Conclusion: This suggests that malaria itself leads to a hearing impairment in mice. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
18. Glatiramer acetate reduces the risk for experimental cerebral malaria: a pilot study.
- Author
-
Lackner, Peter, Part, Andrea, Burger, Christoph, Dietmann, Anelia, Broessner, Gregor, Helbok, Raimund, Reindl, Markus, Schmutzhard, Erich, and Beer, Ronny
- Subjects
CEREBRAL malaria ,MORTALITY ,DRUGS ,MULTIPLE sclerosis ,PLASMODIUM ,APOPTOSIS ,IMMUNE response - Abstract
Background: Cerebral malaria (CM) is associated with high mortality and morbidity caused by a high rate of transient or persistent neurological sequelae. Studies on immunomodulatory and neuroprotective drugs as ancillary treatment in murine CM indicate promising potential. The current study was conducted to evaluate the efficacy of glatiramer acetate (GA), an immunomodulatory drug approved for the treatment of relapsing remitting multiple sclerosis, in preventing the death of C57Bl/6J mice infected with Plasmodium berghei ANKA. Methods and Results: GA treatment led to a statistically significant lower risk for developing CM (57.7% versus 84.6%) in treated animals. The drug had no effect on the course of parasitaemia. The mechanism of action seems to be an immunomodulatory effect since lower IFN-gamma levels were observed in treated animals in the early course of the disease (day 4 post-infection) which also led to a lower number of brain sequestered leukocytes in treated animals. No direct neuro-protective effect such as an inhibition of apoptosis or reduction of micro-bleedings in the brain was found. Conclusion: These findings support the important role of the host immune response in the pathophysiology of murine CM and might lead to the development of new adjunctive treatment strategies. [ABSTRACT FROM AUTHOR]
- Published
- 2009
- Full Text
- View/download PDF
19. Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders.
- Author
-
Mader, Simone, Gredler, Viktoria, Schanda, Kathrin, Rostasy, Kevin, Dujmovic, Irena, Pfaller, Kristian, Lutterotti, Andreas, Jarius, Sven, Di Pauli, Franziska, Kuenz, Bettina, Ehling, Rainer, Hegen, Harald, Deisenhammer, Florian, Aboul-Enein, Fahmy, Storch, Maria K, Koson, Peter, Drulovic, Jelena, Kristoferitsch, Wolfgang, Berger, Thomas, and Reindl, Markus
- Abstract
Background: Serum autoantibodies against the water channel aquaporin-4 (AQP4) are important diagnostic biomarkers and pathogenic factors for neuromyelitis optica (NMO). However, AQP4-IgG are absent in 5-40% of all NMO patients and the target of the autoimmune response in these patients is unknown. Since recent studies indicate that autoimmune responses to myelin oligodendrocyte glycoprotein (MOG) can induce an NMO-like disease in experimental animal models, we speculate that MOG might be an autoantigen in AQP4-IgG seronegative NMO. Although high-titer autoantibodies to human native MOG were mainly detected in a subgroup of pediatric acute disseminated encephalomyelitis (ADEM) and multiple sclerosis (MS) patients, their role in NMO and High-risk NMO (HR-NMO; recurrent optic neuritis-rON or longitudinally extensive transverse myelitis-LETM) remains unresolved.Results: We analyzed patients with definite NMO (n = 45), HR-NMO (n = 53), ADEM (n = 33), clinically isolated syndromes presenting with myelitis or optic neuritis (CIS, n = 32), MS (n = 71) and controls (n = 101; 24 other neurological diseases-OND, 27 systemic lupus erythematosus-SLE and 50 healthy subjects) for serum IgG to MOG and AQP4. Furthermore, we investigated whether these antibodies can mediate complement dependent cytotoxicity (CDC). AQP4-IgG was found in patients with NMO (n = 43, 96%), HR-NMO (n = 32, 60%) and in one CIS patient (3%), but was absent in ADEM, MS and controls. High-titer MOG-IgG was found in patients with ADEM (n = 14, 42%), NMO (n = 3, 7%), HR-NMO (n = 7, 13%, 5 rON and 2 LETM), CIS (n = 2, 6%), MS (n = 2, 3%) and controls (n = 3, 3%, two SLE and one OND). Two of the three MOG-IgG positive NMO patients and all seven MOG-IgG positive HR-NMO patients were negative for AQP4-IgG. Thus, MOG-IgG were found in both AQP4-IgG seronegative NMO patients and seven of 21 (33%) AQP4-IgG negative HR-NMO patients. Antibodies to MOG and AQP4 were predominantly of the IgG1 subtype, and were able to mediate CDC at high-titer levels.Conclusions: We could show for the first time that a subset of AQP4-IgG seronegative patients with NMO and HR-NMO exhibit a MOG-IgG mediated immune response, whereas MOG is not a target antigen in cases with an AQP4-directed humoral immune response. [ABSTRACT FROM AUTHOR]- Published
- 2011
- Full Text
- View/download PDF
20. Cerebrospinal fluid findings in patients with myelin oligodendrocyte glycoprotein (MOG) antibodies. Part 2: Results from 108 lumbar punctures in 80 pediatric patients.
- Author
-
Jarius S, Lechner C, Wendel EM, Baumann M, Breu M, Schimmel M, Karenfort M, Marina AD, Merkenschlager A, Thiels C, Blaschek A, Salandin M, Leiz S, Leypoldt F, Pschibul A, Hackenberg A, Hahn A, Syrbe S, Strautmanis J, Häusler M, Krieg P, Eisenkölbl A, Stoffels J, Eckenweiler M, Ayzenberg I, Haas J, Höftberger R, Kleiter I, Korporal-Kuhnke M, Ringelstein M, Ruprecht K, Siebert N, Schanda K, Aktas O, Paul F, Reindl M, Wildemann B, and Rostásy K
- Subjects
- Adolescent, Autoantibodies blood, Child, Child, Preschool, Encephalomyelitis blood, Encephalomyelitis cerebrospinal fluid, Female, Humans, Immunoglobulins blood, Infant, Male, Retrospective Studies, Spinal Puncture, Autoantibodies cerebrospinal fluid, Encephalomyelitis immunology, Immunoglobulins cerebrospinal fluid, Myelin-Oligodendrocyte Glycoprotein immunology, Oligoclonal Bands cerebrospinal fluid
- Abstract
Background: New-generation, cell-based assays have demonstrated a robust association of serum autoantibodies to full-length human myelin oligodendrocyte glycoprotein (MOG-IgG) with (mostly recurrent) optic neuritis, myelitis, and brainstem encephalitis, as well as with neuromyelitis optica (NMO)-like or acute-disseminated encephalomyelitis (ADEM)-like presentations. However, only limited data are yet available on cerebrospinal fluid (CSF) findings in MOG-IgG-associated encephalomyelitis (MOG-EM; also termed MOG antibody-associated disease, MOGAD)., Objective: To describe systematically the CSF profile in children with MOG-EM., Material and Methods: Cytological and biochemical findings (including white cell counts [WCC] and differentiation; frequency and patterns of oligoclonal bands; IgG/IgM/IgA and albumin concentrations and CSF/serum ratios; intrathecal IgG/IgM/IgA fractions; locally produced IgG/IgM/IgA concentrations; immunoglobulin class patterns; IgG/IgA/IgM reibergrams; Link index; measles/rubella/zoster [MRZ] reaction; other anti-viral and anti-bacterial antibody indices; CSF total protein; CSF L-lactate) from 108 lumbar punctures in 80 pediatric patients of mainly Caucasian descent with MOG-EM were analyzed retrospectively., Results: Most strikingly, CSF-restricted oligoclonal IgG bands, a hallmark of multiple sclerosis (MS), were absent in 89% of samples (N = 96), and the MRZ reaction, the most specific laboratory marker of MS known so far, in 100% (N = 29). If present at all, intrathecal IgG synthesis was low, often transient and mostly restricted to acute attacks. Intrathecal IgM synthesis was present in 21% and exclusively detectable during acute attacks. CSF WCC were elevated in 54% of samples (median 40 cells/μl; range 6-256; mostly lymphocytes and monocytes; > 100/μl in 11%). Neutrophils were present in 71% of samples; eosinophils, activated lymphocytes, and plasma cells were seen only rarely (all < 7%). Blood-CSF barrier dysfunction (as indicated by an elevated albumin CSF/serum ratio) was present in 46% of all samples (N = 79) and at least once in 48% of all patients (N = 67) tested. CSF alterations were significantly more frequent and/or more pronounced in patients with acute spinal cord or brain disease than in patients with acute ON and varied strongly depending on attack severity. CSF L-lactate levels correlated significantly with the spinal cord lesions load (measured in vertebral segments) in patients with acute myelitis (p = 0.0099). An analysis of pooled data from the pediatric and the adult cohort showed a significant relationship of QAlb (p < 0.0005), CST TP (p < 0.0001), and CSF L-lactate (p < 0.0003) during acute attacks with age., Conclusion: MOG-IgG-associated EM in children is characterized by CSF features that are distinct from those in MS. With regard to most parameters, no marked differences between the pediatric cohort and the adult cohort analyzed in Part 1 were noted. Our findings are important for the differential diagnosis of pediatric MS and MOG-EM and add to the understanding of the immunopathogenesis of this newly described autoimmune disease.
- Published
- 2020
- Full Text
- View/download PDF
21. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 3: Brainstem involvement - frequency, presentation and outcome.
- Author
-
Jarius S, Kleiter I, Ruprecht K, Asgari N, Pitarokoili K, Borisow N, Hümmert MW, Trebst C, Pache F, Winkelmann A, Beume LA, Ringelstein M, Stich O, Aktas O, Korporal-Kuhnke M, Schwarz A, Lukas C, Haas J, Fechner K, Buttmann M, Bellmann-Strobl J, Zimmermann H, Brandt AU, Franciotta D, Schanda K, Paul F, Reindl M, and Wildemann B
- Subjects
- Adolescent, Adult, Age Factors, Blood-Brain Barrier pathology, Brain Stem diagnostic imaging, Cohort Studies, Disability Evaluation, Encephalitis blood, Encephalitis diagnostic imaging, Encephalitis immunology, Female, Humans, Interferon-beta therapeutic use, Magnetic Resonance Imaging, Male, Middle Aged, Myelitis blood, Myelitis immunology, Myelitis pathology, Neuromyelitis Optica drug therapy, Neuromyelitis Optica immunology, Rituximab therapeutic use, Young Adult, Brain Stem physiopathology, Immunoglobulin G blood, Myelin-Oligodendrocyte Glycoprotein immunology, Neuromyelitis Optica blood, Neuromyelitis Optica diagnostic imaging
- Abstract
Background: Myelin oligodendrocyte glycoprotein antibodies (MOG-IgG) are present in a subset of aquaporin-4 (AQP4)-IgG-negative patients with optic neuritis (ON) and/or myelitis. Little is known so far about brainstem involvement in MOG-IgG-positive patients., Objective: To investigate the frequency, clinical and paraclinical features, course, outcome, and prognostic implications of brainstem involvement in MOG-IgG-positive ON and/or myelitis., Methods: Retrospective case study., Results: Among 50 patients with MOG-IgG-positive ON and/or myelitis, 15 (30 %) with a history of brainstem encephalitis were identified. All were negative for AQP4-IgG. Symptoms included respiratory insufficiency, intractable nausea and vomiting (INV), dysarthria, dysphagia, impaired cough reflex, oculomotor nerve palsy and diplopia, nystagmus, internuclear ophthalmoplegia (INO), facial nerve paresis, trigeminal hypesthesia/dysesthesia, vertigo, hearing loss, balance difficulties, and gait and limb ataxia; brainstem involvement was asymptomatic in three cases. Brainstem inflammation was already present at or very shortly after disease onset in 7/15 (47 %) patients. 16/21 (76.2 %) brainstem attacks were accompanied by acute myelitis and/or ON. Lesions were located in the pons (11/13), medulla oblongata (8/14), mesencephalon (cerebral peduncles; 2/14), and cerebellar peduncles (5/14), were adjacent to the fourth ventricle in 2/12, and periaqueductal in 1/12; some had concomitant diencephalic (2/13) or cerebellar lesions (1/14). MRI or laboratory signs of blood-brain barrier damage were present in 5/12. Cerebrospinal fluid pleocytosis was found in 11/14 cases, with neutrophils in 7/11 (3-34 % of all CSF white blood cells), and oligoclonal bands in 4/14. Attacks were preceded by acute infection or vaccination in 5/15 (33.3 %). A history of teratoma was noted in one case. The disease followed a relapsing course in 13/15 (87 %); the brainstem was involved more than once in 6. Immunosuppression was not always effective in preventing relapses. Interferon-beta was followed by new attacks in two patients. While one patient died from central hypoventilation, partial or complete recovery was achieved in the remainder following treatment with high-dose steroids and/or plasma exchange. Brainstem involvement was associated with a more aggressive general disease course (higher relapse rate, more myelitis attacks, more frequently supratentorial brain lesions, worse EDSS at last follow-up)., Conclusions: Brainstem involvement is present in around one third of MOG-IgG-positive patients with ON and/or myelitis. Clinical manifestations are diverse and may include symptoms typically seen in AQP4-IgG-positive neuromyelitis optica, such as INV and respiratory insufficiency, or in multiple sclerosis, such as INO. As MOG-IgG-positive brainstem encephalitis may take a serious or even fatal course, particular attention should be paid to signs or symptoms of additional brainstem involvement in patients presenting with MOG-IgG-positive ON and/or myelitis.
- Published
- 2016
- Full Text
- View/download PDF
22. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome.
- Author
-
Jarius S, Ruprecht K, Kleiter I, Borisow N, Asgari N, Pitarokoili K, Pache F, Stich O, Beume LA, Hümmert MW, Ringelstein M, Trebst C, Winkelmann A, Schwarz A, Buttmann M, Zimmermann H, Kuchling J, Franciotta D, Capobianco M, Siebert E, Lukas C, Korporal-Kuhnke M, Haas J, Fechner K, Brandt AU, Schanda K, Aktas O, Paul F, Reindl M, and Wildemann B
- Subjects
- Adolescent, Adult, Age Distribution, Aged, Aquaporin 4 immunology, Brain diagnostic imaging, Cardiolipins immunology, Child, Cohort Studies, Female, HEK293 Cells, Humans, Male, Middle Aged, Myelin-Oligodendrocyte Glycoprotein genetics, Optic Nerve diagnostic imaging, Sex Factors, Vaccination methods, Vision Disorders etiology, Young Adult, Anti-Inflammatory Agents therapeutic use, Autoantibodies cerebrospinal fluid, Myelin-Oligodendrocyte Glycoprotein immunology, Neuromyelitis Optica cerebrospinal fluid, Neuromyelitis Optica diagnostic imaging, Neuromyelitis Optica epidemiology, Neuromyelitis Optica therapy, Treatment Outcome
- Abstract
Background: A subset of patients with neuromyelitis optica spectrum disorders (NMOSD) has been shown to be seropositive for myelin oligodendrocyte glycoprotein antibodies (MOG-IgG)., Objective: To describe the epidemiological, clinical, radiological, cerebrospinal fluid (CSF), and electrophysiological features of a large cohort of MOG-IgG-positive patients with optic neuritis (ON) and/or myelitis (n = 50) as well as attack and long-term treatment outcomes., Methods: Retrospective multicenter study., Results: The sex ratio was 1:2.8 (m:f). Median age at onset was 31 years (range 6-70). The disease followed a multiphasic course in 80 % (median time-to-first-relapse 5 months; annualized relapse rate 0.92) and resulted in significant disability in 40 % (mean follow-up 75 ± 46.5 months), with severe visual impairment or functional blindness (36 %) and markedly impaired ambulation due to paresis or ataxia (25 %) as the most common long-term sequelae. Functional blindess in one or both eyes was noted during at least one ON attack in around 70 %. Perioptic enhancement was present in several patients. Besides acute tetra-/paraparesis, dysesthesia and pain were common in acute myelitis (70 %). Longitudinally extensive spinal cord lesions were frequent, but short lesions occurred at least once in 44 %. Fourty-one percent had a history of simultaneous ON and myelitis. Clinical or radiological involvement of the brain, brainstem, or cerebellum was present in 50 %; extra-opticospinal symptoms included intractable nausea and vomiting and respiratory insufficiency (fatal in one). CSF pleocytosis (partly neutrophilic) was present in 70 %, oligoclonal bands in only 13 %, and blood-CSF-barrier dysfunction in 32 %. Intravenous methylprednisolone (IVMP) and long-term immunosuppression were often effective; however, treatment failure leading to rapid accumulation of disability was noted in many patients as well as flare-ups after steroid withdrawal. Full recovery was achieved by plasma exchange in some cases, including after IVMP failure. Breakthrough attacks under azathioprine were linked to the drug-specific latency period and a lack of cotreatment with oral steroids. Methotrexate was effective in 5/6 patients. Interferon-beta was associated with ongoing or increasing disease activity. Rituximab and ofatumumab were effective in some patients. However, treatment with rituximab was followed by early relapses in several cases; end-of-dose relapses occurred 9-12 months after the first infusion. Coexisting autoimmunity was rare (9 %). Wingerchuk's 2006 and 2015 criteria for NMO(SD) and Barkhof and McDonald criteria for multiple sclerosis (MS) were met by 28 %, 32 %, 15 %, 33 %, respectively; MS had been suspected in 36 %. Disease onset or relapses were preceded by infection, vaccination, or pregnancy/delivery in several cases., Conclusion: Our findings from a predominantly Caucasian cohort strongly argue against the concept of MOG-IgG denoting a mild and usually monophasic variant of NMOSD. The predominantly relapsing and often severe disease course and the short median time to second attack support the use of prophylactic long-term treatments in patients with MOG-IgG-positive ON and/or myelitis.
- Published
- 2016
- Full Text
- View/download PDF
23. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: Frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin.
- Author
-
Jarius S, Ruprecht K, Kleiter I, Borisow N, Asgari N, Pitarokoili K, Pache F, Stich O, Beume LA, Hümmert MW, Trebst C, Ringelstein M, Aktas O, Winkelmann A, Buttmann M, Schwarz A, Zimmermann H, Brandt AU, Franciotta D, Capobianco M, Kuchling J, Haas J, Korporal-Kuhnke M, Lillevang ST, Fechner K, Schanda K, Paul F, Wildemann B, and Reindl M
- Subjects
- Adult, Aquaporin 4 genetics, Autoantibodies cerebrospinal fluid, Female, HEK293 Cells, Humans, Male, Myelin-Oligodendrocyte Glycoprotein genetics, Neuromyelitis Optica cerebrospinal fluid, Neuromyelitis Optica physiopathology, Severity of Illness Index, Transfection, Aquaporin 4 immunology, Autoantibodies blood, Myelin-Oligodendrocyte Glycoprotein immunology, Myelitis immunology, Neuromyelitis Optica blood, Neuromyelitis Optica immunology
- Abstract
Background: Antibodies to myelin oligodendrocyte glycoprotein (MOG-IgG) have been suggested to play a role in a subset of patients with neuromyelitis optica and related disorders., Objective: To assess (i) the frequency of MOG-IgG in a large and predominantly Caucasian cohort of patients with optic neuritis (ON) and/or myelitis; (ii) the frequency of MOG-IgG among AQP4-IgG-positive patients and vice versa; (iii) the origin and frequency of MOG-IgG in the cerebrospinal fluid (CSF); (iv) the presence of MOG-IgG at disease onset; and (v) the influence of disease activity and treatment status on MOG-IgG titers., Methods: 614 serum samples from patients with ON and/or myelitis and from controls, including 92 follow-up samples from 55 subjects, and 18 CSF samples were tested for MOG-IgG using a live cell-based assay (CBA) employing full-length human MOG-transfected HEK293A cells., Results: MOG-IgG was detected in 95 sera from 50 patients with ON and/or myelitis, including 22/54 (40.7 %) patients with a history of both ON and myelitis, 22/103 (21.4 %) with a history of ON but no myelitis and 6/45 (13.3 %) with a history of longitudinally extensive transverse myelitis but no ON, and in 1 control patient with encephalitis and a connective tissue disorder, all of whom were negative for AQP4-IgG. MOG-IgG was absent in 221 further controls, including 83 patients with AQP4-IgG-seropositive neuromyelitis optica spectrum disorders and 85 with multiple sclerosis (MS). MOG-IgG was found in 12/18 (67 %) CSF samples from MOG-IgG-seropositive patients; the MOG-IgG-specific antibody index was negative in all cases, indicating a predominantly peripheral origin of CSF MOG-IgG. Serum and CSF MOG-IgG belonged to the complement-activating IgG1 subclass. MOG-IgG was present already at disease onset. The antibodies remained detectable in 40/45 (89 %) follow-up samples obtained over a median period of 16.5 months (range 0-123). Serum titers were higher during attacks than during remission (p < 0.0001), highest during attacks of simultaneous myelitis and ON, lowest during acute isolated ON, and declined following treatment., Conclusions: To date, this is the largest cohort studied for IgG to human full-length MOG by means of an up-to-date CBA. MOG-IgG is present in a substantial subset of patients with ON and/or myelitis, but not in classical MS. Co-existence of MOG-IgG and AQP4-IgG is highly uncommon. CSF MOG-IgG is of extrathecal origin. Serum MOG-IgG is present already at disease onset and remains detectable in the long-term course. Serum titers depend on disease activity and treatment status.
- Published
- 2016
- Full Text
- View/download PDF
24. T cell-activation in neuromyelitis optica lesions plays a role in their formation.
- Author
-
Pohl M, Kawakami N, Kitic M, Bauer J, Martins R, Fischer MT, Machado-Santos J, Mader S, Ellwart JW, Misu T, Fujihara K, Wekerle H, Reindl M, Lassmann H, and Bradl M
- Subjects
- Animals, Aquaporin 4 metabolism, Astrocytes immunology, Astrocytes pathology, Brain pathology, Cell Line, Cells, Cultured, Encephalomyelitis, Autoimmune, Experimental immunology, Encephalomyelitis, Autoimmune, Experimental pathology, Immunoglobulin G metabolism, Interferon-gamma metabolism, Macrophages immunology, Macrophages pathology, Microglia pathology, Microglia physiology, Multiple Sclerosis immunology, Multiple Sclerosis pathology, Neuromyelitis Optica pathology, Rats, Inbred Lew, Receptors, IgG metabolism, Spinal Cord pathology, T-Lymphocytes pathology, Brain immunology, Neuromyelitis Optica immunology, Spinal Cord immunology, T-Lymphocytes physiology
- Abstract
Background: Neuromyelitis optica (NMO) is an inflammatory demyelinating disease of the central nervous system (CNS), which is characterized by the presence of pathogenic serum autoantibodies against aquaporin 4 (AQP4) in the vast majority of patients. The contribution of T cells to the formation of astrocyte destructive lesions is currently unclear. However, active human NMO lesions contain CD4+ T-lymphocytes expressing the activation marker Ox40, and the expression is more profound compared to that seen in MS lesions of comparable activity. Therefore, we analyzed the role of T-cell activation within the CNS in the initiation of NMO lesions in an experimental model of co-transfer of different encephalitogenic T-cells and human AQP4 antibody containing NMO immunoglobulin (NMO IgG). We further studied the expression of the T-cell activation marker Ox40 in NMO and multiple sclerosis lesions in different stages of activity., Results: All encephalitogenic T-cell lines used in our experiments induced brain inflammation with a comparable extent of blood brain barrier damage, allowing human NMO IgG to penetrate into the brain and spinal cord tissue. However, astrocyte destructive NMO lesions were only seen with T-cells, which showed signs of activation in the lesions. T-cell activation was reflected by the expression of the activation marker Ox40 and pronounced production of γ-IFN, which was able to increase the production of complement proteins and of the Fc gamma III receptor (Fcgr3) and decreased production of complement inhibitory protein Factor H in microglia., Conclusions: Our data indicate that local activation of T-cells provide an inflammatory environment in the CNS, which allows AQP4 auto-antibodies to induce astrocyte destructive NMO-like lesions.
- Published
- 2013
- Full Text
- View/download PDF
25. Intrastriatal injection of interleukin-1 beta triggers the formation of neuromyelitis optica-like lesions in NMO-IgG seropositive rats.
- Author
-
Kitic M, Hochmeister S, Wimmer I, Bauer J, Misu T, Mader S, Reindl M, Fujihara K, Lassmann H, and Bradl M
- Subjects
- Animals, Aquaporin 4 metabolism, Astrocytes pathology, Astrocytes physiology, Blood-Brain Barrier physiopathology, Cells, Cultured, Chemokine CXCL2 metabolism, Corpus Striatum blood supply, Corpus Striatum pathology, Disease Models, Animal, Endothelial Cells pathology, Endothelial Cells physiology, Gene Expression physiology, Humans, Immunoglobulin G metabolism, Interferon-gamma metabolism, Interleukin-1beta administration & dosage, Interleukin-6 metabolism, Microglia pathology, Microglia physiology, Multiple Sclerosis pathology, Multiple Sclerosis physiopathology, Neuromyelitis Optica pathology, Rats, Inbred Lew, Recombinant Proteins metabolism, Tumor Necrosis Factor-alpha metabolism, Corpus Striatum physiopathology, Interleukin-1beta metabolism, Neuromyelitis Optica physiopathology
- Abstract
Background: Neuromyelitis optica (NMO) is a severe, disabling disease of the central nervous system (CNS) characterized by the formation of astrocyte-destructive, neutrophil-dominated inflammatory lesions in the spinal cord and optic nerves. These lesions are initiated by the binding of pathogenic aquaporin 4 (AQP4)-specific autoantibodies to astrocytes and subsequent complement-mediated lysis of these cells. Typically, these lesions form in a setting of CNS inflammation, where the blood-brain barrier is open for the entry of antibodies and complement. However, it remained unclear to which extent pro-inflammatory cytokines and chemokines contribute to the formation of NMO lesions. To specifically address this question, we injected the cytokines interleukin-1 beta, tumor necrosis factor alpha, interleukin-6, interferon gamma and the chemokine CXCL2 into the striatum of NMO-IgG seropositive rats and analyzed the tissue 24 hours later by immunohistochemistry., Results: All injected cytokines and chemokines led to profound leakage of immunoglobulins into the injected hemisphere, but only interleukin-1 beta induced the formation of perivascular, neutrophil-infiltrated lesions with AQP4 loss and complement-mediated astrocyte destruction distant from the needle tract. Treatment of rat brain endothelial cells with interleukin-1 beta, but not with any other cytokine or chemokine applied at the same concentration and over the same period of time, caused profound upregulation of granulocyte-recruiting and supporting molecules. Injection of interleukin-1 beta caused higher numbers of blood vessels with perivascular, cellular C1q reactivity than any other cytokine tested. Finally, the screening of a large sample of CNS lesions from NMO and multiple sclerosis patients revealed large numbers of interleukin-1 beta-reactive macrophages/activated microglial cells in active NMO lesions but not in MS lesions with comparable lesion activity and location., Conclusions: Our data strongly suggest that interleukin-1 beta released in NMO lesions and interleukin-1 beta-induced production/accumulation of complement factors (like C1q) facilitate neutrophil entry and BBB breakdown in the vicinity of NMO lesions, and might thus be an important secondary factor for lesion formation, possibly by paving the ground for rapid lesion growth and amplified immune cell recruitment to this site.
- Published
- 2013
- Full Text
- View/download PDF
26. Fibrinogen is not elevated in the cerebrospinal fluid of patients with multiple sclerosis.
- Author
-
Ehling R, Pauli FD, Lackner P, Kuenz B, Santner W, Lutterotti A, Gneiss C, Hegen H, Schocke M, Deisenhammer F, Berger T, and Reindl M
- Abstract
Background: Elevated plasma fibrinogen levels are a well known finding in acute infectious diseases, acute stroke and myocardial infarction. However its role in the cerebrospinal fluid (CSF) of acute and chronic central (CNS) and peripheral nervous system (PNS) diseases is unclear., Findings: We analyzed CSF and plasma fibrinogen levels together with routine parameters in patients with multiple sclerosis (MS), acute inflammatory diseases of the CNS (bacterial and viral meningoencephalitis, BM and VM) and PNS (Guillain-Barré syndrome; GBS), as well as in non-inflammatory neurological controls (OND) in a total of 103 patients. Additionally, MS patients underwent cerebral MRI scans at time of lumbar puncture.CSF and plasma fibrinogen levels were significantly lower in patients with MS and OND patients as compared to patients with BM, VM and GBS. There was a close correlation between fibrinogen levels and albumin quotient (rho = 0.769, p < 0.001) which strongly suggests passive transfer of fibrinogen through the blood-CSF-barrier during acute inflammation. Hence, in MS, the prototype of chronic neuroinflammation, CSF fibrinogen levels were not elevated and could not be correlated to clinical and neuroradiological outcome parameters., Conclusions: Although previous work has shown clear evidence of the involvement of fibrinogen in MS pathogenesis, this is not accompanied by increased fibrinogen in the CSF compartment.
- Published
- 2011
- Full Text
- View/download PDF
27. Antibodies to myelin oligodendrocyte glycoprotein in HIV-1 associated neurocognitive disorder: a cross-sectional cohort study.
- Author
-
Lackner P, Kuenz B, Reindl M, Morandell M, Berger T, Schmutzhard E, and Eggers C
- Subjects
- AIDS Dementia Complex drug therapy, AIDS Dementia Complex pathology, AIDS Dementia Complex physiopathology, Adult, Anti-HIV Agents therapeutic use, Autoantibodies immunology, Brain immunology, Brain pathology, Brain physiopathology, Cohort Studies, Cross-Sectional Studies, Female, HIV-1 immunology, Humans, Inflammation immunology, Middle Aged, Myelin Proteins, Myelin-Oligodendrocyte Glycoprotein, RNA, Viral blood, Sensitivity and Specificity, Viral Load, AIDS Dementia Complex metabolism, Autoantibodies blood, Autoantibodies cerebrospinal fluid, Myelin-Associated Glycoprotein immunology
- Abstract
Background: Neuroinflammation and demyelination have been suggested as mechanisms causing HIV-1 associated neurocognitive disorder (HAND). This cross-sectional cohort study explores the potential role of antibodies to myelin oligodendrocyte glycoprotein (MOG), a putative autoantigen in multiple sclerosis, in the pathogenesis of HAND., Methods: IgG antibodies against MOG were measured by ELISA in sera and cerebrospinal fluid (CSF) of 65 HIV-positive patients with HAND (n = 14), cerebral opportunistic infections (HIVOI, n = 25), primary HIV infection (HIVM, n = 5) and asymptomatic patients (HIVasy, n = 21). As control group HIV-negative patients with bacterial or viral CNS infections (OIND, n = 18) and other neurological diseases (OND, n = 22) were included. In a subset of HAND patients MOG antibodies were determined before and during antiviral therapy., Results: In serum, significantly higher MOG antibody titers were observed in HAND compared to OND patients. In CSF, significantly higher antibody titers were observed in HAND and HIVOI patients compared to HIVasy and OND patients and in OIND compared to OND patients. CSF anti-MOG antibodies showed a high sensitivity and specificity (85.7% and 76.2%) for discriminating patients with active HAND from asymptomatic HIV patients. MOG immunopositive HAND patients performed significantly worse on the HIV dementia scale and showed higher viral load in CSF. In longitudinally studied HAND patients, sustained antibody response was noted despite successful clearance of viral RNA., Conclusions: Persistence of MOG antibodies despite viral clearance in a high percentage of HAND patients suggests ongoing neuroinflammation, possibly preventing recovery from HAND.
- Published
- 2010
- Full Text
- View/download PDF
28. Opposed circulating plasma levels of endothelin-1 and C-type natriuretic peptide in children with Plasmodium falciparum malaria.
- Author
-
Dietmann A, Lackner P, Helbok R, Spora K, Issifou S, Lell B, Reindl M, Kremsner PG, and Schmutzhard E
- Subjects
- Analysis of Variance, Animals, Antimalarials therapeutic use, Case-Control Studies, Child, Child, Preschool, Drug Combinations, Endothelium, Vascular immunology, Enzyme-Linked Immunosorbent Assay, Female, Gabon epidemiology, Humans, Infant, Malaria, Falciparum blood, Malaria, Falciparum drug therapy, Malaria, Falciparum parasitology, Male, Pyrimethamine therapeutic use, Quinine therapeutic use, Statistics, Nonparametric, Sulfadoxine therapeutic use, Endothelin-1 blood, Malaria, Falciparum immunology, Natriuretic Peptide, C-Type blood, Plasmodium falciparum immunology
- Abstract
Background: Molecular mechanisms involved in the pathogenesis of severe Plasmodium falciparum malaria (SM), are not yet fully understood. Both endothelin-1 (ET-1) and C-type natriuretic peptide (CNP) are produced by vascular endothelium and act locally as paracrine regulators of vascular tone, ET-1 being a potent vasoconstrictor and CNP having strong vasorelaxant properties., Methods: Plasma levels of ET-1 and N-terminal fragments of CNP (NT-proCNP) were studied on admission and after 24 hours of treatment, using enzyme-linked-immunosorbent-assay (ELISA) technique, in Gabonese children with severe falciparum malaria (SM, n = 50), with uncomplicated malaria (UM, n = 39) and healthy controls (HC, n = 25)., Results: Compared to HC, malaria patients had significantly higher plasma levels of ET-1 and significantly lower levels of NT-proCNP (p < 0.001 and p < 0.024 respectively). Plasma levels of NT-proCNP were additionally decreased in SM patients compared to HC (p = 0.034), whereas UM was not significantly different to HC. In the SM group we found a trend towards lower ET-1 levels compared to UM (p = 0.085)., Conclusion: In the present study, an imbalance between the vasoconstricitve and vasorelaxant endothelium-derived substances ET-1 and CNP in the plasma of children with falciparum malaria is demonstrated, presumably in favor of vasoconstrictive and pro-inflammatory effects. These results may indicate involvement of ET-1 and CNP in malaria pathogenesis. Furthermore, results of lower ET-1 and CNP levels in SM may reflect endothelial cell damage.
- Published
- 2008
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.